FeesSafety
Pluang+

FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.

Market News
22 Nov 2026, 13:07 WIB
Lee Samaha
View Source
Neutral
FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.

Grail expects FDA approval for its multi-cancer early detection test, Galleri, in Q1 2027, which could lead to Medicare and commercial insurer coverage. Despite a failed primary endpoint in a large NHS trial, Galleri showed promising results for 12 deadly cancers, supporting FDA approval hopes. The test's commercial success hinges on insurer adoption and pricing, with management targeting a $500-$600 price range. Next steps include FDA approval, insurer negotiations, and a Medicare National Coverage Analysis.

Grail stock's outlook in 2026 is framed here with a look at the health sector's market breadth on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 22, 2026 13:21 WIB: out of 150 priced health-sector US stocks, 31 rose and 117 fell. Notable movers include BRKR (Bruker Corporation Common Stock) down 9.07% at USD 56.47, DNA (Ginkgo Bioworks Holdings Inc) down 9.02% at USD 7.46, and HIMS (Hims and Hers Health Inc) down 8.86% at USD 14.60, with typical hold times ranging from 10 to 24 days on Pluang.

More News

Super Micro raises 2027 revenue forecast to $72-$82B on strong AI demand and improved cash flow.

Super Micro raises 2027 revenue forecast to $72-$82B on strong AI demand and improved cash flow.

Super Micro Computer raised its fiscal 2027 revenue guidance to $72 billion to $82 billion, a 12% increase from the previous target, driven by strong demand for AI hardware and faster customer deployment schedules. The company improved its cash conve...

Company Fundamentals
Bullish
22 minutes ago
e.l.f. Beauty raises full-year sales outlook amid strong growth and Rhode acquisition boost

e.l.f. Beauty raises full-year sales outlook amid strong growth and Rhode acquisition boost

e.l.f. Beauty reported a 51% year-over-year sales increase for the September quarter, driven by the Rhode acquisition and strong organic growth of about 35%. The company raised its full-year sales guidance to 22%-24%, with organic growth expected at ...

Company Fundamentals
Bullish
40 minutes ago
Nextdoor Q3 revenue rises 14% as active users hit record 24.5M, driven by organic growth and self-serve ads.

Nextdoor Q3 revenue rises 14% as active users hit record 24.5M, driven by organic growth and self-serve ads.

Nextdoor reported a 14% year-over-year revenue increase to $79 million in Q3 2026, driven by a record 24.5 million weekly active users. The company is growing user engagement organically through product improvements rather than paid ads, with self-se...

Company Fundamentals
Bullish
45 minutes ago
Growth ETF down 18% since October; dividend ETF up 3%, showing benefits of combining both funds.

Growth ETF down 18% since October; dividend ETF up 3%, showing benefits of combining both funds.

Since early October, the Vanguard Morningstar Growth ETF has dropped about 18% from its record high, while the Schwab U.S. Dividend Equity ETF has risen roughly 3%. The growth ETF focuses on fast-growing tech and consumer stocks with high earnings gr...

Market News
Bullish
1 hour ago
Yelp shifts focus to AI and data licensing as ad revenue dips, targeting $250M non-ad revenue by 2028

Yelp shifts focus to AI and data licensing as ad revenue dips, targeting $250M non-ad revenue by 2028

Yelp reported a 1% decline in Q3 2026 net revenue to $371 million due to weak local advertising demand. To counter this, the company is expanding AI-powered services like Yelp Host, which now handles 2.5 million calls annually, and aims to grow non-a...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App